Urgent considerations for booster vaccination strategies against Ebola virus disease
Article in The Lancet Infectious Diseases (May 2024)
The most recent citing publications are shown below. View all 6 publications that cite this research output on Dimensions.
Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial
Article in The Lancet Infectious Diseases (March 2024)
Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial
Article in Human Vaccines & Immunotherapeutics (March 2024)